# LB1410

Source: https://onco.cc/drugs/lb1410/  
OnCo record `lb1410` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

LB1410 is an experimental bispecific antibody from L & L Bio, Ningbo, China in phase 2 trials, aimed at PD-1 and TIM-3.

## Summary

LB1410 is a bispecific antibody developed by L & L Bio, Ningbo, China. Its targets are PD-1 and TIM-3 (the sponsor names PD-1 x TIM3). The sponsor states: Anti-PD-1/TIM3 bispecific antibody intended to block dual immune checkpoint pathways, given in combination with LB4330. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT06468358, plans to enrol 194 participants with primary completion expected 2026-12-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: bispecific antibody
- Mechanism: Anti-PD-1/TIM3 bispecific antibody intended to block dual immune checkpoint pathways, given in combination with LB4330.

## Sources

- ClinicalTrials.gov: trials of LB1410: https://clinicaltrials.gov/search?intr=LB1410

## Connected records

- targets: [PD-1](https://onco.cc/targets/pd1/), [TIM-3](https://onco.cc/targets/tim3/)
- companies: [Hutchmed](https://onco.cc/companies/hutchmed/)
- trials: [A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct06468358/)

---
JSON: https://onco.cc/api/v1/entities/lb1410.json